In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel full for ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) among patients with metabolic ...

The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

With the growing demand for GLP-1 drugs for weight loss, a high percentage of medication users are experiencing temporary and long-term side effects from these rapid weight loss methods. Kelker Pharma ...